Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
02/2003
02/26/2003CN1399626A Ethers of o-desmethyl venlafaxine
02/26/2003CN1399622A Triphenylalkene derivatives and their use as selective estrogen receptor modulators
02/26/2003CN1399573A Use of phthalazine derivatives
02/26/2003CN1399562A Method of treating lupus based on antibody affinity and screening methods and compositions for use thereof
02/26/2003CN1399514A Model animal of mesangial cell proliferative nephritis
02/26/2003CN1398621A Kidney-invigorating capsule and its prepn
02/26/2003CA2420656A1 Antisense oligonucleotides against vanilloid receptor 1
02/26/2003CA2419744A1 A novel crystal of n-hydroxy-2(s)-methyl-5-ethoxymethoxy-4(s)-¬n-(4-phenoxyphenylcarbonyl)amino|pentanamide and a method for the preparation thereof and a pharmaceutical agent comprising the same as active ingredient
02/25/2003US6525202 Cyclic amine phenyl beta-3 adrenergic receptor agonists
02/25/2003US6525067 Substituted heterocyclic derivatives
02/25/2003US6525059 Substituted pyrazoles as p38 kinase inhibitors
02/25/2003US6525058 1-ethyl methylester 4-((3- (p-(carboxyamidino)phenyl) -2-oxo-5-oxazolidinyl)methyl)-1-piperazineacetate; Gantofiban; antagonistic action to Glycoprotein GPIIb/IIIa receptor; oily base; gantofiban citrate
02/25/2003US6525048 Aminomethylphenoxymethyl/benzisoxazole substituted azabicyclic compounds; depression, generalized anxiety disorder, obesity, migraine; 2-(5-Fluoro-benzo(d)isoxazol-3-y)-7-(3-morpholin-4-ylmethylphenoxymethyl) -octahydro-pyrido(1,2-a)pyrazine;
02/25/2003US6525047 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair
02/25/2003US6525036 Compounds and compositions as protease inhibitors
02/25/2003US6524840 Polynucleotides, host cell expression systems, the encoded proteins, polypeptides and peptides
02/25/2003US6524813 Novel polynucleotides and polypeptides of the spo0J family derived from Staphylococcus
02/25/2003US6524608 Intravesical drug delivery system
02/22/2003CA2355573A1 Method for the synthesis of peptide salts, their use and the pharmaceutical preparations, containing peptide salts
02/21/2003WO2002020462A1 Benzoic acid derivatives and drugs containing the same as the active ingredient
02/21/2003CA2419722A1 Benzoic acid derivatives and drugs containing the same as the active ingredient
02/20/2003WO2003014731A2 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use
02/20/2003WO2003014316A2 Immunomodulatory compositions, formulations, and methods for use thereof
02/20/2003WO2003014296A2 A group of novel anti-cancer compounds with specific structure
02/20/2003WO2003014294A2 Tacis and br3 polypeptides and uses thereof
02/20/2003WO2003014287A1 Hops extracts, method for the production and use
02/20/2003WO2003014158A1 Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use
02/20/2003WO2003014141A1 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents
02/20/2003WO2003014137A1 Adenosine a3 receptor agonists
02/20/2003WO2003014124A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists
02/20/2003WO2003014112A1 Crystal and process for producing the same
02/20/2003WO2003014105A1 Bicyclic compound, production and use as hiv inhibitors
02/20/2003WO2003014090A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
02/20/2003WO2003014086A1 Process for the preparation of amorphous form of torsemide
02/20/2003WO2003014083A1 Spiro compounds
02/20/2003WO2003014064A1 Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
02/20/2003WO2003013656A2 Non-peptide ccr1 receptor antagonists for the treatment of progressive renal fibrosis
02/20/2003WO2003013605A1 Remedies for prostatic diseases
02/20/2003WO2003013588A1 Kidney regeneration material comprising cells and cell growth factor
02/20/2003WO2003013586A1 Access control system
02/20/2003WO2003013560A1 Herbal composition for treatment of chronic renal failure and method to produce thereof
02/20/2003WO2003013545A1 Novel benzo-fused heterocycles as endothelin antagonisits
02/20/2003WO2003013530A2 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists
02/20/2003WO2003013528A1 Substituted pyridin-4-ones and their use as gonadotropin-releasing hormone receptor antagonists.
02/20/2003WO2003013517A1 Aminoisoxazole derivatives active as kinase inhibitors
02/20/2003WO2003013513A1 Stable emulsion composition
02/20/2003WO2003013493A1 Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs
02/20/2003WO2003013492A1 Combination therapy for the treatment of neurological disorders
02/20/2003WO2003013475A1 Injectable foam and novel pharmaceutical applications thereof
02/20/2003WO2003013434A2 Methods and compositions for treating diseases associated with excesses in ace
02/20/2003WO2003013432A2 Methods of use for novel sulfur containing organic nitrate compounds
02/20/2003WO2002086085A3 Human timp-1 antibodies
02/20/2003WO2002085871A3 Serotonergic agents with long-acting in vivo effects
02/20/2003WO2002085368A3 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
02/20/2003WO2002074742A3 Cdk-inhibitory indirubin derivatives having an increased solubility
02/20/2003WO2002072585A3 Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics
02/20/2003WO2002070525A3 Nitrogen-based camptothecin derivatives
02/20/2003WO2002068399B1 Aryl carbamate derivatives, preparation and use thereof
02/20/2003WO2002064126A3 Method of treating of demyelinating diseases or conditions
02/20/2003WO2002049993A3 High affinity small molecule c5a receptor modulators
02/20/2003WO2002045738A3 Vaccine composition containing transforming growth factor alpha
02/20/2003WO2002030882A9 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
02/20/2003WO2002030860A9 Ketone compounds and compositions for cholesterol management and related uses
02/20/2003WO2002024635A3 Aminoalcohol derivatives
02/20/2003WO2001093850B1 Methods and compositions using sulodexide for the treatment of diabetic nephropathy
02/20/2003US20030036651 As phosphodiesterase inhibitor for prophylaxis and therapy of bronchial asthma; pneumonic diseases, pulmonary emphysema, chronic obstructive pulmonary disease acute respiratory distress syndrome (ARDS), and other respiratory diseases
02/20/2003US20030036642 Platelet derived growth factor (PDGF) nucleic acid ligand complexes
02/20/2003US20030036552 Novel compounds
02/20/2003US20030036543 Especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
02/20/2003US20030036199 Kit for use in the diagnosis and treatment of cancer
02/20/2003US20030035835 Protective overcoatings
02/20/2003US20030035832 Compression of drug and adjuvant
02/20/2003CA2607992A1 Bicyclic compound, production and use thereof
02/20/2003CA2456881A1 Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use
02/20/2003CA2456744A1 Adenosine a3 receptor agonists
02/20/2003CA2456599A1 Spiro compounds
02/20/2003CA2456533A1 Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs
02/20/2003CA2456328A1 Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof
02/20/2003CA2456144A1 A group of novel anti-cancer compounds with specific structure
02/20/2003CA2456124A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists
02/20/2003CA2456103A1 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives
02/20/2003CA2455871A1 Substituted pyridin-4-ones and their use as gonadotropin-releasing hormone receptor antagonists.
02/20/2003CA2455759A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
02/20/2003CA2455754A1 Amine derivatives
02/20/2003CA2455631A1 Aminoisoxazole derivatives active as kinase inhibitors
02/20/2003CA2454417A1 Novel benzo-fused heterocycles as endothelin antagonists
02/20/2003CA2453995A1 Tacis and br3 polypeptides and uses thereof
02/20/2003CA2453890A1 Crystal and process for producing the same
02/20/2003CA2453433A1 Methods of use for novel sulfur containing organic nitrate compounds
02/20/2003CA2451914A1 Combination therapy for the treatment of neurological disorders
02/19/2003EP1284272A1 Estra-1,3,5(10)-triene derivatives
02/19/2003EP1284268A1 Thiazolidinedione derivative and its use as antidiabetic
02/19/2003EP1284266A1 Novel indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof
02/19/2003EP1283886A2 Intracellular signaling proteins
02/19/2003EP1283884A2 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor
02/19/2003EP1283848A2 Protein complexes and assays for screening anti-cancer agents
02/19/2003EP1283835A2 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators
02/19/2003EP1283828A1 Novel polymorph v of torasemide
02/19/2003EP1283827A2 Caspase inhibitors and uses thereof
02/19/2003EP1133491B1 Novel benzofurane derivatives, preparation method, use as medicines and pharmaceutical compositions containing same
1 ... 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 ... 562